Emma Louise Wynne

Title: Emma Louise Wynne: Innovator in Therapeutic Compounds

Introduction

Emma Louise Wynne is a notable inventor based in London, GB. She has made significant contributions to the field of therapeutic compounds, particularly in the development of innovative triazolo compounds. Her work focuses on compounds that have the potential to inhibit AXL receptor tyrosine kinase function, which is crucial in the treatment of various diseases.

Latest Patents

Emma holds a patent for her invention titled "[1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use." This patent pertains to certain triazolo compounds, referred to as TAZ compounds, which are designed to inhibit AXL receptor tyrosine kinase function. The invention also includes pharmaceutical compositions comprising these compounds, which can be utilized both in vitro and in vivo to treat conditions mediated by AXL receptor tyrosine kinase, including proliferative conditions such as cancer. She has 1 patent to her name.

Career Highlights

Emma is currently associated with Cancer Research Technology Limited, where she continues her research and development in therapeutic innovations. Her work is pivotal in advancing the understanding and treatment of diseases linked to AXL receptor tyrosine kinase.

Collaborations

Emma has collaborated with esteemed colleagues, including Laurent Jean Martin Rigoreau and James Donald Firth. Their combined expertise contributes to the advancement of research in therapeutic compounds.

Conclusion

Emma Louise Wynne is a pioneering inventor whose work in therapeutic compounds is making a significant impact in the medical field. Her innovative approach to inhibiting AXL receptor tyrosine kinase function holds promise for the treatment of serious health conditions.